Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.

Kanbayashi, Yuko; Kobayashi, Momoko; Anzai, Miku; Shimizu, Tadashi; Uchida, Mayako

Kanbayashi, Yuko; Kobayashi, Momoko; Anzai, Miku; Shimizu, Tadashi; Uchida, Mayako.

Afiliação

Kanbayashi Y; Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kobayashi M; Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
Anzai M; Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
Shimizu T; School of Pharmacy, Hyogo Medical University, Kobe, Japan.
Uchida M; Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.

Oncology ; 101(12): 817-821, 2023.

Article em En | MEDLINE | ID: mdl-37591211

Assuntos

Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Doenças Pulmonares Intersticiais; Humanos; Anticorpos Monoclonais Humanizados/efeitos adversos; Pulmão; Doenças Pulmonares Intersticiais/induzido quimicamente

Palavras-chave

Japanese Adverse Drug Event Report database; Lung adverse events; Outcome; Pembrolizumab; Time to onset

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Tipo de estudo: Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google